Form 4 for QDEL QuidelOrtho Corp
Accepted 2022-06-01 00:00:00 ET · period of report 2022-05-27 · accession 0000899243-22-020490 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2022-06-01 | 2022-05-27 | QDEL | Strobeck Matthew | Dir | A - Grant | — | +54.8K | 38.1K | New | — |
| D | 2022-06-01 | 2022-05-27 | QDEL | Strobeck Matthew | Dir | A - Grant | — | +6,533 | 6,533 | New | — |
| DM | 2022-06-01 | 2022-05-27 | QDEL | Strobeck Matthew | Dir | A - Grant | $0.00 | +1,908 | 259 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-27 | A | A | 16,630 | — | 16,630 | I Birchview | — | — | (F1) Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. (F3) The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| 2 | Common | Common Stock | 2022-05-27 | A | A | 38,145 | — | 38,145 | I | — | — | (F1) Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. |
| 3 | Common | Common Stock | 2022-05-27 | A | A | 6,533 | — | 6,533 | D UGMA Account | — | — | (F1) Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. (F2) The Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| 4 | Derivative | Restricted Stock Units | 2022-05-27 | A | A | 875 | $0.00 | 875 | D | — · — to — | 875 Common Stock | (F6) Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. (F8) Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| 5 | Derivative | Restricted Stock Units | 2022-05-27 | A | A | 262 | $0.00 | 262 | D | — · — to — | 262 Common Stock | (F6) Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. (F8) Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| 6 | Derivative | Restricted Stock Units | 2022-05-27 | A | A | 427 | $0.00 | 427 | D | — · — to — | 427 Common Stock | (F6) Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. (F8) Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| 7 | Derivative | Restricted Stock Units | 2022-05-27 | A | A | 85 | $0.00 | 85 | D | — · — to — | 85 Common Stock | (F6) Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. (F8) Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| 8 | Derivative | Non-Qualified Stock Options | 2022-05-27 | A | A | 259 | $0.00 | 259 | D | $53.27 · — to 2028-04-04 | 259 Common Stock | (F5) Vested in full. |